{"name":"Cantex Pharmaceuticals","slug":"cantex-pharmaceuticals","ticker":"","exchange":"","domain":"cantex.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Azeliragon 10 mg","genericName":"Azeliragon 10 mg","slug":"azeliragon-10-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Azeliragon 10 mg","genericName":"Azeliragon 10 mg","slug":"azeliragon-10-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gJBVV95cUxQem1QNkZoLXZKWURKcEVVRTVKMjJ1aTJuMHU2RVJQMTBJN012RTkzbnMtU0FsYkZPOTc4elhjWjJ2OHk3VjZvZDdkdTZfVnIwQ0FGbHNGZVRpUmI3M29XM041ZFhXeS1TMzJVd2lpZ3RkTEU5Rk9NYnhwd0tYcnpkcTFyYkJERHdRUHdRek05T0wzU2lmY3lwUW1CM1pYY1VIRjcxUFdzNXV1aHdSZW82MEljYjg0NFFYbEFSQTJXMWNDSXJjT0UwOWJONkxtUTNoZWlEY1VZWHl0c000NGcyLWxGd0RQdURFWnVweDBYTWNYbndfVU9Od2laVXVUZzJmdG03dFRvbVRVNE1maVdFWG5PbmxGMzRIODdKb0NrSlE3a24xUlQ0N3o2ZFNHbVhyOEN3d2tZZ3BZeHozVVhLYTBaY1kxVWpXV09wc0NOREhQRG92T3Q2RkplOFlqMUkxejFrOWlGNDRVRUJJRVpuU3dB?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPRGdKaXRfVFdEcDVnTGdQRFd4NEVRejk5eTNwNXltMFJBZWlmTTlORk1tWWxPd3VmOW9rSDQ3OEE4dGU0M2wtTlF3cmNVS0RnY0o1WmpGNjl0RTltZDJiVmRVOXBjaVcyTDUwYXN2NmxnUDhUVTVsZzZESFB0SXkzX1c4cVVyZXN4ZURDT3FFaE1JV2sxcjc3S01fTll0Z1JSay0xZnBNd1l4ZTlwX2JUVGhTR1MydXl4UjNreklqYTB2bG9BZlZKQWRpbUlKamZ3REltc3ZFS3JpN01zTlFOT2NxNFFYdk01WTFBVGZ1UjltZWRPYktCOGdtVU9OZENMRERCXzZwOGNHaHI2U1ZQV1pwYkx4Q1hEWDFrZGQwZDdrT3FiUXpNckdhWm1PMnUzdWpsV3ktZzNUeWNC?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire UK","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire UK","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVHdLOUpTX2x1a2FoeVVnU1BQTWVlcS1wZWd3ZXM4a1hNclNremVCMi1uY1lhckhkbmNIdXQwbzhzVzE0aC1QME1HNWFYVWxoUlh6c3VaQlpPSG5QOFRyc3h3Y04tYlZuazhtdnZmU0sxR2dlN1F5SHhLZnpNZjdQZFlvN0c2dzlFWW5EVFcxUm94NXFua0pVakUySDFLdmVqaDFlajYxWm1RUQ?oc=5","date":"2025-08-20","type":"pipeline","source":"BioSpace","summary":"5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development - BioSpace","headline":"5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPYWstM01ybThPVVl1Q3poMjVBZnJaRHBsTGhCeGpWU0UyZEVYbm00OGdibFU2OG83b21sMUhmZ1h5T1M0N1ByQWtySzVyNVZpM0w1TGs2aTZMeTh5TWNzZEtXdW1JU1E3M3NBeGlsVi1ya25LV3BMQnVxT3RoNlZ1bGhwS3lJalNhZnZRSmNPdDhFWEh5LUw4QWEwbVdubUFqeUtpeUJHeWlQTUozeTdVa01QNXZsVXB2VzJPaWR5N0JXYlE1LUZ4Q2dDREZZWFQ2UUFCa3F3?oc=5","date":"2024-12-16","type":"pipeline","source":"refreshmiami.com","summary":"8+ things to know in #MiamiTech: News from The Underline, Strive305, Cantex, Nova, UM & why digital nomads love Miami - refreshmiami.com","headline":"8+ things to know in #MiamiTech: News from The Underline, Strive305, Cantex, Nova, UM & why digital nomads love Miami","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcF9KLU8wYjRWQ2l2ODI4TjdyMkx0b1Y4dm5FUFd5STdLY2k1WTllWkxneDdRV2JsbnBfc3hSc24zTUdxdVdpbVBiY29SQk5oRldrMUN1LVhyZF9xZUM4eWtaWmhSSXJ0QTlaR0FESGRISmYzRHNxT3BIYjRJZXUtTTA0eGhkV2ktTFp3dy1CQ3czZlU3anh6Ui13ZERiazJvYjRKTHQxTngwNGpyUWtzTGRGVWhsSkhiZGVIVFdZRGstYjhVTXl6SEVPMmxyRjdldE5v?oc=5","date":"2024-05-28","type":"pipeline","source":"BioSpace","summary":"CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - BioSpace","headline":"CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSGhrenNzZFpQanlIMGc1dU1YVlV5Y0tocmgta1Bfa29VN24tdGliWlVvNG5FRGZ6OFR4QlRYMElORmF1OWhISXJKVDNveVZzZG50T0xNMkNmdE53dnhrV2EtUnNjMXAzZ0tfWHprMU9fQjYzS3F3elFJSHM5MUQzZmZWRldVZTluMzl3a1ZsLS10RU5QUTVCR1dXa0Rhb3E1ZnRtVENkWGItVTJicV9aemVNQW5ZMldESlZ0YlFWZGZaQQ?oc=5","date":"2024-04-16","type":"trial","source":"The Clinical Trial Vanguard","summary":"Cantex Pharma’s Azeliragon Therapy: A Potential Cancer Breakthrough - The Clinical Trial Vanguard","headline":"Cantex Pharma’s Azeliragon Therapy: A Potential Cancer Breakthrough","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNd0ZxSmI2T08xSVhLejdQRTNxLXZNdG5BZFkyX01PUlB6RmNLVHpJVVZJaDVycXBxQXBQbDhIcEF6Unk3dUVwQWliTWtoVm1DelpwM0pCczVXWEFXbF82U3JLT2wzR2Z6dl84VTlEWUxMQ3psNFplMmNWak5FbzdObGlLaGRsXzNzaDBibjRubnNhMVgwYnBVeGk5YmY1ZEFCRzBlZ1BqLWd4UURXZFFDYjhuUmY?oc=5","date":"2022-02-24","type":"deal","source":"pharmaphorum","summary":"Cantex secures license to develop small molecule-drug for inflammatory lung diseases - pharmaphorum","headline":"Cantex secures license to develop small molecule-drug for inflammatory lung diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOSlByeGp0cGVvdEpGLU5ibGIydWk3Sm1KMTFzd0llNVktUlM0cVhWNlZXdkJMTlJoQ08teHFQV2hoUHFuZVFmQ3JlV0hHX2hlRkZSQ3NaOFhNak94Q3dGNXNHQWFjMXBmZEdDVk9pVnZNclZoZjM3eGN5bUxseHNJWElsRkVIN1VRbHFXSjU1cXdVN1AxRzFvNGxzNU5HRmdJSUJtZHh6ZGJNWFF4M2tBanZTMU5PZDNQaGdoeFpPSDJYeU1xOEtlTkJRc3VZT1ZqX0djVjIxVFh3OVFnS00wZkNtMWM2T3B4M2pzQzRSM1RpZHlRODFfN3B5UGRvenlHUlpiRjRDajJRNWloZDNxSWU0Y2txc0Mxc1NIUDE4djFpSHlsU1NrUkh2Yw?oc=5","date":"2022-02-23","type":"deal","source":"Wyss Institute at Harvard","summary":"Cantex licenses intellectual property from Harvard University to develop repurposed drug identified by Wyss Institute to treat inflammatory lung diseases including COVID-19 - Wyss Institute at Harvard","headline":"Cantex licenses intellectual property from Harvard University to develop repurposed drug identified by Wyss Institute to","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}